Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04319224 · ClinicalTrials.gov registry record · Phase 1
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
A Phase 1 study, sponsored by Jounce Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04319224: Clinical Trial Phase 1 study, sponsored by Jounce Therapeutics.
NCT04319224 is a Phase 1 study that was terminated before completion, run by Jounce Therapeutics. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04319224, a Phase 1 study, was terminated before completion, sponsored by Jounce Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
JTX-2011-R01 is an open label, multicenter, rollover study that is designed to provide continued access to vopratelimab for eligible subjects with advanced solid tumor malignancies who have previously participated in a vopratelimab study (the parent study).
Primary Outcome
Percentage of subjects with at least one AE
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Vopratelimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-03-10 |
| Est. Completion | 2023-01-03 |
| Phase | Phase 1 |
Why NCT04319224 stopped before completion
NCT04319224 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT04319224 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04319224 about?
NCT04319224 is a clinical study titled "Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors". JTX-2011-R01 is an open label, multicenter, rollover study that is designed to provide continued access to vopratelimab for eligible subjects with advanced solid tumor malignancies who have previously participated in a vopratelimab study (the parent study).
What is the current status of trial NCT04319224?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2020-03-10. Estimated completion is 2023-01-03.
What interventions are being tested in trial NCT04319224?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Vopratelimab (DRUG).
Who is sponsoring clinical trial NCT04319224?
This trial is sponsored by Jounce Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04319224's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI